DuP 721

Class: Oxazolidinone

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Active against S. aureus, with equal activity against MRSA as MSSA.
Institute where first reported:	DuPont (Bristol-Myers Squibb, UK)
Year first mentioned:	1987
Highest developmental phase:	Phase 1
Development status:	Inactive
Reason Dropped:	Entered phase I study but was dropped, however in rats it was found to be lethal (1) Toxicity was weight loss / wasting. An early oxazolidinone; linezolid was the first successful one (LS).

Chemical structure(s):
Canonical SMILES:	CC(=O)C1=CC=C(C=C1)N2CC(CNC(=O)C)OC2=O
Isomeric SMILES:	CC(=O)C1=CC=C(C=C1)N2CC(OC2=O)CNC(=O)C
InChI:	InChI=1S/C14H16N2O4/c1-9(17)11-3-5-12(6-4-11)16-8-13(20-14(16)19)7-15-10(2)18/h3-6,13H,7-8H2,1-2H3,(H,15,18)
InChI Key:	POXUJOYUVLWPQN-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/122686

External links:
Guide to Pharmacology:	DuP-721
Citations:	https://books.google.co.uk/books?id=_HFitfA4OcUC&pg=PA178&lpg=PA178&dq=DuP+721+phase+1&source=bl&ots=inRvcfCNtS&sig=1Igumvoss_5XbM6KZsGxdUysR4s&hl=en&sa=X&ei=Ind1VaHmOoX_UIKzgOAJ&ved=0CCEQ6AEwAA#v=onepage&q=DuP%20721%20phase%201&f=false http://www.ncbi.nlm.nih.gov/pmc/articles/PMC172119/pdf/aac00080-0190.pdf